Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Pharmacogenetics and individual responses to treatment of hyperglycemia in type 2 diabetes

Research output: Contribution to journalReviewResearchpeer-review

  1. Re: The recent paper 'Genetic determinants of impaired awareness of hypoglycaemia in type 1 diabetes'

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. The effects of inherited NUDT15 polymorphisms on thiopurine active metabolites in Japanese children with acute lymphoblastic leukemia

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Nomenclature for alleles of the human carboxylesterase 1 gene

    Research output: Contribution to journalComment/debateResearchpeer-review

  4. Patients with prolonged effect of succinylcholine or mivacurium had novel mutations in the butyrylcholinesterase gene

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Haploinsufficiency of ARHGAP42 is associated with hypertension

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Genetic Determinants of Weight Loss After Bariatric Surgery

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Metformin-induced changes of the gut microbiota in healthy young men: results of a non-blinded, one-armed intervention study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Protein-coding variants implicate novel genes related to lipid homeostasis contributing to body-fat distribution

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

The aim of this study was to summarize current knowledge and provide perspectives on the relationships between human genetic variants, type 2 diabetes, antidiabetic treatment, and disease progression. Type 2 diabetes is a complex disease with clear-cut diagnostic criteria and treatment guidelines. Yet, the interindividual response to therapy and slope of disease progression varies markedly among patients with type 2 diabetes. Gene-gene, gene-environment, and gene-treatment interactions may explain some of the variation in disease progression. Several genetic variants have been suggested to be associated with response to antidiabetic drugs. Some are present in drug receptors or drug metabolizers (OCT genes, KCNJ11, ABCC8, and CYP2C9). Numerous type 2 diabetes risk variants have been identified, but genetic risk score models applying these variants have failed to identify 'disease progressors' among patients with diabetes. Although genetic risk scores are based on a few known loci and only explain a fraction of the heritability of type 2 diabetes, it seems that the genes responsible for the development of diabetes may not be the same driving disease progression after the diagnosis has been made. Pharmacogenetic interactions explain some of the interindividual variation in responses to antidiabetic treatment and may provide the foundation for future genotype-based treatment standards.

Original languageEnglish
JournalPharmacogenetics and Genomics
Volume25
Issue number10
Pages (from-to)475-84
Number of pages10
ISSN1744-6872
DOIs
Publication statusPublished - Oct 2015

    Research areas

  • Diabetes Mellitus, Type 2, Disease Progression, Humans, Hyperglycemia, Hypoglycemic Agents, Pharmacogenetics, Journal Article, Research Support, Non-U.S. Gov't, Review

ID: 51900938